A study of the efficacy and tolerability of capecitabine and lobaplatin in advanced HER-2 negative breast cancer patients

Yuan Yuan; Lili Zhang; Zhe Zhang; Yu Qian; Yue Teng

doi:10.21037/atm-21-2702

A study of the efficacy and tolerability of capecitabine and lobaplatin in advanced HER-2 negative breast cancer patients

Ann Transl Med. 2021 Jul;9(14):1151. doi: 10.21037/atm-21-2702.

Authors

Yuan Yuan¹, Lili Zhang¹, Zhe Zhang², Yu Qian³, Yue Teng¹

Affiliations

¹ Department of Chemotherapy, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
² Department of Pathology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
³ Department of Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.

Abstract

Background: This study sought to examine the efficacy and adverse reactions of capecitabine and lobaplatin in the treatment of metastatic human epidermal growth factor receptor 2 (HER-2) negative breast cancer (BC).

Methods: This retrospective study examined 45 patients diagnosed with advanced HER-2 negative BC. Patients were enrolled in this study from November 2015 to June 2019. The patients received capecitabine and lobaplatin combination therapy. The therapeutic efficacy and side effects were evaluated after at least 2 cycles of treatment.

Results: Therapeutic efficacy and adverse reactions were evaluated in 38 patients, comprising 12 cases of partial response (PR), 19 cases of stable disease (SD), and 7 cases of progressive disease (PD). Among these, 3 patients required treatment delays or dose reductions for subsequent cycles, and 2 patients discontinued treatment. The overall response rate (ORR) was 31.58% and the disease control rate (DCR) was 81.58%. The ORR and DCR for hormone receptor positive, HER-2 negative (HR+/HER-2-) and triple negative breast cancer (TNBC) patients were 31.82% and 31.25%, and 86.36% and 75%, respectively. The median progression free survival (PFS) was 8 months, 6 months, and 6 months in patients receiving the therapeutics as a first-line, second-line, or third-line and beyond treatment, respectively. The main side effects were myelosuppression, including granulocytopenia, thrombocytopenia, and anemia. Among patients with grade 1 side effects or above, 28 patients (73.68%) had myelosuppression, and 13 patients (34.21%) had gastrointestinal reactions. Further, we investigated the association between side effects and clinical outcomes, and found that PFS was increased in patients with myelosuppression and gastrointestinal reactions.

Conclusions: Capecitabine and lobaplatin combination therapy was effective and well tolerated among patients with advanced HER-2 negative BC.

Keywords: Advanced breast cancer; HER-2 negative; capecitabine; lobaplatin; side effects.